Cell kinetic analysis of human brain tumors by in situ double labelling with bromodeoxyuridine and iododeoxyuridine

✍ Scribed by Takao Hoshino; Satoyuki Ito; Akio Asai; Makoto Shibuya; Michael D. Prado; Barbara A. Dodson; Richard L. Davis; Charles B. Wilson

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: French
• Weight: 563 KB
• Volume: 50
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910500102

✦ Synopsis

Fifky-seven patients with brain tumors (29 gliomas, 23 meningiomas, 5 miscellaneous) received infusions of intravenous iododeoxyuridine (IUdR) and bromodeoxyuridine (BUdR) 1-5 hr apart shortly before tumor removal. Excised tumor specimens were stained sequentially for BUdR and IUdR. The percentage of BUdR-labelled cells was determined to establish the labelling index (LI), or S-phase fraction, and the ratio of cells labelled only with lUdR to cells labelled with BUdR or with BUdR and IUdR was determined to calculate the duration of S-phase (Ts) and the potential doubling time (Tp) of each tumor. The BUdR Lls varied from < I% to 20%, reflecting the malignancy of each tumor. Despite the difference in Lls, however, Ts was fairly uniform (mean ? SD, 8.7 & 2.0 hr). Tp varied from 2 days to more than I month and correlated closely with the BUdR Lls (Tp = 23/L1°.93; 8 = 0.91). Double-labelling studies with lUdR and BUdR allow the S-phase fraction, Ts and Tp to be determined from a single biopsy specimen and thus provide more useful information on the growth characteristics of individual tumors than can be obtained by single-labelling studies with BUdR.